Controversies in the therapy of low-grade glioma: When and how to treat

Expert Review of Anticancer Therapy

Volumn 2, Issue 5, 2002, Pages 529-536

  Brandes, Alba A ^a   Vastola, Francesca ^a   Basso, Umberto ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Chemotherapy; Low grade gliomas; Radiotherapy; Review; Surgery

Indexed keywords

CYTOTOXIC AGENT; LOMUSTINE; PROCARBAZINE; PROTEIN P53; TEMOZOLOMIDE; VINCRISTINE;

ADULT; ASTROCYTOMA; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CHROMOSOMAL LOCALIZATION; CHROMOSOME 17P; CHROMOSOME LOSS; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG SAFETY; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; NEUTROPENIA; OLIGODENDROGLIOMA; ONSET AGE; PROGNOSIS; RADIATION DOSE; REVIEW; SURGICAL TECHNIQUE; TREATMENT INDICATION; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE; CLINICAL TRIAL; GENETICS; GLIOMA; RADIOTHERAPY;

AGE OF ONSET; CLINICAL TRIALS; GLIOMA; HUMANS; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY;

EID: 0036797842     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.2.5.529     Document Type: Review

References (49)

1. World Health Organization Classification of Tumors. Pathology and Genetics: Tumors of the Nervous system. Kleihues P and Cavanee WK (Eds). IARC press, Lyon (2000).
2. Olson JD, Riedel E, DeAngelis LM. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 54, 1442-1448 (2000).
3. Piepmeier J, Christopher S, Spencer D et al. Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. Neurosurgery 38, 872-879 (1996).
4. Pignatti F, Van den Bent M, Curran D et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J. Clin. Oncol. 20, 2076-2084 (2002).
5. Shaw EG, Scheithauer BW, O'Fallen JR. Supratentorial gliomas: a comparative study by grade and histologic type. J. Neurooncol. 31, 273-278 (1997).
6. Brandes AA, Fiorentino MV. Pathological and therapeutic aspects of oligodendroglioma. Cancer Treat. Pev. 24, 110-111 (1998).
7. Barker FG, Chang SM, Huhn SL et al. Age and the risk of anaplasia in magnetic resonance non-enhancing supratentorial cerebral tumors. Cancer 80, 936-941 (1997).
8. Recht LD, Lew R, Smith TW. Suspected low-grade gliomas: is deferring treatment safe? Ann. Neurol. 31, 431-436 (1992).
9. Nozaki M, Tada M, Kobayashi H et al. Roles of the functional loss of P53 and other genes in astrocytoma tumorigenesis and progression. Neurooncol. 1, 124-137 (1999).
10. Perry A, Anderl KA, Borell TJ. Detection of P16, RB, CDK4 and P53 gene deletion amplification by fluorescence in situ hybridization (FISH) in 96 gliomas. Am. J. Clin. Pathol. 112, 801-809 (1999).
11. Wang SI, Puc J, Li J et al. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res. 57, 4183-4186 (1997).
12. Von Deimling, Louis DN, von Ammon K. Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas and mixed gliomas. Cancer Res. 52, 4277-4279 (1992).
13. Smith JS, Perry A, Borell TJ et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas and mixed oligoastrocytomas. J. Clin. Oncol. 18, 636-645 (2000).
14. Cairncross JG, Ueki K, Zlatescu MC et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst, 90, 1473-1479 (1998).
15. Leighton C, Fisher B, Bauman G et al. Supratentorial low-grade gliomas in adults: an analysis of prognostic factors and timing of radiation. J. Clin. Oncol. 15, 1294-1301 (1997).
16. Lote K, Egeland T, Hager B et al. Survival, prognostic factors and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients. J. Clin. Oncol. 15, 3129-3140 (1997).
17. Van Veelen MLC, Avezaat CJJ, Kros Jm et al. Supratentorial low-grade astrocytoma: prognostic factors, dedifferentiation and issue of early venus late surgery. J. Neurosurg. Psychiatry 64, 581-587 (1998).
18. Donahue B, Scott CB, Nelson JS. et al. Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: a report of radiation therapy oncology group 83-02. Int. J. Radiat. Oncol. Biol. Phys. 38, 911-914 (1997).
19. Vecht CJ. Effect of age on treatment decisions in low-grade glioma. J. Neurol. Neurosurg. Psych. 56, 1259-1264 (1993).
20. Bauman G, Lote K, Larson D et al. Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int. J. Radiat. Oncol. Biol. Phys. 45, 923-929 (1999).
21. Berger NE, Deliganis AV, Dobbins J et al. The effect of extent of resection on recurrence in patients with low-grade cerebral hemisphere gliomas. Cancer 74, 1784-1791 (1994).
22. Cairncross JG, Laperriere M. Low-grade glioma to treat or not to treat? Arch. Neurol. 46, 1238-1242 (1990).
23. Shaw EG. Low-grade gliomas: to treat or not to treat? A radiation oncologist's viewpoint (editorial). Arch. Neurol. 47, 54, (1990)
24. Wilden JN, Kelly PJ. Computerized stereotactic biopsy for low density CT lesion presenting with epilepsy. J. Neurol. Neurosurg. Psychiatry 50, 1302-1305 (1987).
25. Shafqat S, Hedley-White ET, Henson JW. Age-dependent rate of anaplastic transformation in low-grade astrocytoma. Neurol. 52, 867-869 (1999).
26. Reijneveld JC, Sitskoorn MM, Klein M et al. Cognitive status and quality of life in patients with suspected versus proven low-grade gliomas. Neurology 56, 618-623 (2001).
27. Scheibel RS, Meyers CA, Levin MA. Cognitive dysfunction following surgery for intracerebral glioma: influence of histopathology, lesion, location and treatment. J. Neurooncol. 30, 61-69 (1996).
28. Keles GE, Lamborn KR, Berger MS. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J. Neurosurg. 95, 735-745 (2001).
29. Shaw EG, Scheithauer BW, Gilberston DT et al. Postoperative radiotherapy of supratentorial low-grade gliomas. Int. Radiat. Oncol Biol. Phys. 16, 663-668, (1989).
30. Bauman G, Pahapill P, Macdonald D et al. Low-grade glioma: a measuring radiographic response to radiotherapy. Can. J. Neurol. Sci. 26, 18-22 (1999).
31. Karim ABMF, Afra D, Cornu P et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult European organization for research and treatment of cancer study 22845 with the medical research council study BRO4. an interim analysis. Int. J. Radiat. Oncol. Biol. Phys. 52, 316-324 (2002).
32. Brandes A, Pasetto LM, Lumachi F. Endocrine dysfunctions in patients treated for brain tumors. J. Neurooncol. 47, 85-92 (2000).
33. Brandes AA, Rigon A, Monfardini S. Radiotherapy of the brain in the elderly. Contra. Eur. J. Cancer 36, 447-451 (2000).
34. Janny P, Cure H, Mohr M et al. Low-grade supratentorial astrocytomas: Management and prognostic factors. Cancer 73, 1937-1945 (1994).
35. North CA, North RB, Epstein JA et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation therapy. Cancer 66, 6-14 (1990).
36. Taphoorn MJB, Schiphorst AK, Snock FJ et al. Cognitive function and quality of life in patients with low-grade glioma: the impact of radiotherapy. Ann. Neurol. 36, 48-54 (1994)
37. Shaw EG, Arusell R, Scheithauer B et al. A prospective randomized trial of low versus high dose radiation therapy in adults with supratentorial low-grade glioma: initial Report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group Study. J. Clin. Oncol. 20, 2267-2276 (2002).
38. Karim ABMF, Maat B, Hathevoll R. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: EORTC study 22844. Int. J. Radiat. Oncol. Biol. Phys. 36, 549-556 (1996).
39. Rudoler S, Corn BW, Werner-Wasik M et al. Patterns of tumor progression after radiotherapy for low-grade gliomas: analysis from the computed tomography/magnetic resonance imaging era. Am. J. Clin. Oncol. 21, 23-27 (1998).
40. Eyre HJ, Crwley JJ, Townsend JJ et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU fbr incompletely resected low-grade gliomas: a Southwest Oncology Group study. J. Neurosurg. 78, 909-914 (1993).
41. Mason NW, Krol GS, DeAngelis LM. Low-grade oligodendroglioma responds to chemotherapy. Neurol. 46, 203-207 (1996).
42. Buckner JC, Smith JS, Nelson DF et al. Phase II trial of procarbazine, CCNU and vincristine (PCV) as initial therapy in patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy results and associations with chromosome 1p and 19 q loss. Proc. Am. Soc. Clin. Oncol. 18, 140 (1999) (Abstract).
43. Thoron L, Colinskas C, McDevitt K et al. Adjuvant I-PCV chemotherapy for treatment of low-grade oligodendroglioma. Proc. Am. Soc. Clin. Oncol. 16, 410 (1997) (Abstract).
44. Friedman AH, Cokgor I, Edwards S et al. Phase II treatment of anaplastic oligodendroglioma and low-grade glioma with temozolomide. Proc. Am. Soc. Clin. Oncol. 19, 169 (2000) (Abstract).
45. Viviers L, Brada M, Hines F et al. A Phase II trial of primary chemotherapy with temozolomide in patients with low grade cerebral gliomas. Proc. Am. Soc. Clin. Oncol. 19, 167 (2000) (Abstract).
46. Brandes AA, Pasetto LM, Vastola F, Monfardini S. Temozolomide in patients with high grade gliomas. Oncology 59, 181-186 (2000).
47. Brandes AA, Basso U, Paserto LM. New strategy developments in brain tumor therapy. Curr. Pharm. Des. 7, 1553-1580 (2001).
48. Brandes AA, Lacombe D, Vecht C. Future trends in the treatment of brain tumors. Eur. J. Cancer 37, 2297-2301 (2001).
49. Brandes AA, Basso U, Pasetto LM. Changing boundaries in the treatment of malignant gliomas. Expert Rev. Anticancer Ther. 1, 357-370 (2001).